Search results
Results From The WOW.Com Content Network
Romosozumab is used for osteoporosis to decrease the risk of fractures. [10] Two trials found that it reduced the rate of vertebral fracture. In one, there was a 73% lower risk of vertebral fracture after one year, and the benefit was maintained after a second year of taking denosumab.
For premium support please call: 800-290-4726 more ways to reach us
Consequently, these drugs have been researched for the treatment of osteoporosis, [2] [3] [4] though with only limited success. [5] More recent research has suggested a number of additional applications for these drugs, such as hyperresponsiveness and inflammation in allergic asthma. [6] [7] [8] [9]
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, [1] [2] and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND).
Certain medications have been associated with an increase in osteoporosis risk; only glucocorticosteroids and anticonvulsants are classically associated, but evidence is emerging with regard to other drugs. Steroid-induced osteoporosis (SIOP) arises due to use of glucocorticoids – analogous to Cushing's syndrome and involving mainly the axial ...
Osteoporosis drugs taken to prevent bone fracture may cause rare, but critical, fractures of their own, the Food and Drug Administration announced today in a warning to consumers. The agency also ...
Zoledronic acid is used for the treatment of osteoporosis in men and post-menopausal women at increased risk of fracture. [13] [14] In 2007, the US Food and Drug Administration (FDA) approved zoledronic acid for the treatment of postmenopausal osteoporosis. [7] [15]
For example, in clinical trials, the drug strontium ranelate was found to aid bone growth, increase bone density, and lessen vertebral, peripheral, and hip fractures in women. Strontium ranelate is an antiosteoporotic agent which both increases bone formation and reduces bone resorption, resulting in a rebalance of bone turnover in favor of ...